Question

Difficulty: HardMonitoring and Treatment Evaluation

A 22-year-old woman is brought to the emergency department by her roommate due to progressive lethargy, confusion, and recurrent vomiting over the last 48 hours. The patient has a history of bipolar I disorder and generalized tonic-clonic seizures. Her home medications include valproic acid, which was initiated six weeks ago, and a daily multivitamin. She does not use alcohol, tobacco, or illicit drugs.

On presentation, her temperature is 36.8°C (98.2°F), blood pressure is 118/74 mm Hg, pulse is 88/min, and respiratory rate is 14/min. Physical examination shows a somnolent woman who is oriented only to her name. A bilateral flapping tremor of the hands is elicited upon wrist extension. No jaundice, scleral icterus, or abdominal distension is noted.

Laboratory studies are obtained:

TestResultReference Range
Sodium139 mEq/L136-145 mEq/L
Potassium4.1 mEq/L3.5-5.0 mEq/L
Blood urea nitrogen12 mg/dL8-20 mg/dL
Creatinine0.8 mg/dL0.6-1.2 mg/dL
Aspartate aminotransferase (AST)28 U/L10-40 U/L
Alanine aminotransferase (ALT)30 U/L7-56 U/L
Total bilirubin0.7 mg/dL0.1-1.2 mg/dL
Alkaline phosphatase75 U/L44-147 U/L
Valproic acid level82 µg/mL50-125 µg/mL
Venous ammonia180 µmol/L15-45 µmol/L

Which of the following is the most appropriate next step in the management of this patient's current condition?

  1. Discontinue valproic acid and administer intravenous levocarnitineAnswer
  2. B
    Discontinue valproic acid and administer oral lactulose
  3. C
    Decrease the valproic acid dose to target a trough level of 50 µg/mL
  4. D
    Maintain the current valproic acid dose and order an electroencephalogram
  5. E
    Discontinue valproic acid and consult nephrology for emergent hemodialysis

Answer

Discontinue valproic acid and administer intravenous levocarnitine
The correct answer is to discontinue valproic acid and administer intravenous levocarnitine. This patient presents with altered mental status, asterixis, and significantly elevated venous ammonia in the context of recent valproic acid initiation. Notably, her liver function tests (AST, ALT, bilirubin) and her serum valproic acid level are entirely within normal reference limits. This presentation is classic for valproic acid-induced hyperammonemic encephalopathy (VHE). VHE is characterized by elevated ammonia levels leading to encephalopathy without evidence of hepatocellular injury or frank drug overdose. Valproic acid metabolism consumes carnitine, and its toxic metabolites inhibit carbamoyl phosphate synthetase I, a critical, rate-limiting enzyme in the urea cycle. This inhibition leads to the rapid accumulation of ammonia. The definitive management of VHE involves the immediate cessation of the offending agent (valproic acid) and the administration of levocarnitine (L-carnitine). Levocarnitine replenishes systemic carnitine stores, binds to toxic valproic acid metabolites to facilitate their renal excretion, and effectively restores normal urea cycle function.

Step-by-Step Solution

1
Interpret the clinical presentation and laboratory findings.
The patient has altered mental status, asterixis, and hyperammonemia, with completely normal liver function tests and a therapeutic valproic acid level.
This specific constellation points to a metabolic encephalopathy rather than primary hepatocellular failure.
2
Identify the underlying pharmacological syndrome.
The clinical picture is diagnostic for valproic acid-induced hyperammonemic encephalopathy (VHE).
Valproic acid can disrupt the urea cycle and cause severe hyperammonemia without concurrent liver injury, often occurring even when serum drug levels are within the normal therapeutic range.
3
Determine the targeted treatment for this condition.
The correct intervention is immediate discontinuation of valproic acid and administration of levocarnitine.
Levocarnitine replenishes the carnitine stores that are depleted by valproic acid metabolism, thereby rescuing the urea cycle and enabling the excretion of ammonia.

Key Concept

Valproic acid-induced hyperammonemic encephalopathy can occur despite normal liver function tests and therapeutic serum drug levels; the definitive treatment is immediate discontinuation of the drug and administration of levocarnitine.
Estimated Time:1m 30s
Rate this question